Molgradex Misses Primary Endpoint in Alveolar Pulmonary Proteinosis Trial
The safety and efficacy of Molgradex was evaluated in a double blind, placebo controlled trial involving 138 patients with aPAP.
The safety and efficacy of Molgradex was evaluated in a double blind, placebo controlled trial involving 138 patients with aPAP.
The FDA has granted Fast Track designation to Molgradex (molgramostim; Savara) for the treatment of autoimmune pulmonary alveolar proteinosis.
This article is part of MPR‘s coverage of the American Academy of Allergy, Asthma & Immunology annual meeting, taking place in San Francisco, California. Our staff will report on medical research related to asthma, allergy, and other respiratory conditions, conducted by experts in the field. Check back regularly for more news from AAAAI 2019. SAN FRANCISCO — Prenatal…
There was an association between 25(OH)D deficiency and increased prevalence of interstitial lung abnormalities 10 years later.
The researchers found that 12% of infants in the high-flow group received escalation of care due to treatment failure versus 23% in the standard-therapy group.
There was variation in pharmacotherapy and radiography use by network and site (P<0.001), with intersite ranges from 2 to 79% and 1.6 to 81%, respectively.
The researchers found that the 2-year airflow decline-free survival was 32.8 and 41.3% with azithromycin and placebo, respectively (unadjusted hazard ratio, 1.3).
Results showed that the ivacaftor/tezacaftor group reached the primary endpoint with a mean absolute improvement in ppFEV1 of 4% points from baseline vs. placebo (P<0.0001).
The researchers found that new antibiotic treatment was associated with an increased likelihood of recovery to 90% of baseline (P<0.001), especially for hospitalization compared to no new antibiotic.
Eighty-eight percent of telehealth visits for ARI were new utilization; increase in net spending per user.